

ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE V1.1 EVALUATION FORM 2C

For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalence studies

Name of study:	<input type="text"/>		
Study medicine:	<input type="text"/>	Indication:	<input type="text"/>
First author:	<input type="text"/>	Year:	<input type="text"/>
		Journal:	<input type="text"/>
Name of evaluator:	<input type="text"/>		

Primary outcome is Toxicity or Quality of Life AND Non-inferiority Studies

- GRADE 4** Reduced toxicity or improved QoL (using a validated scale) with evidence for statistical non-inferiority or superiority in PFS/OS
- GRADE 3** Improvement in some symptoms (using a validated scale) BUT without evidence of improved overall QoL

Primary outcome is Response Rate

- GRADE 2** RR is increased $\geq 20\%$ but no improvement in toxicity/QoL/PFS/OS
- GRADE 1** RR is increased $< 20\%$ but no improvement in toxicity/QoL/PFS/OS

Mark with \checkmark if relevant

Final magnitude of clinical benefit grade	4	3	2	1
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Non-curative setting grading - 5 and 4 indicates a substantial magnitude of clinical benefit